CNCE Archives - BioTuesdays

Developments

Concert Pharmaceuticals launches Phase 3 alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) initiated a Phase 3 trial to evaluate CTP-543 for the treatment of alopecia areata. Alopecia areata is an autoimmune disease that causes partial or complete loss of hair on the...

November 3, 2020

Developments

Concert completes enrollment in Phase 2 schizophrenia trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its Phase 2 study evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia. The trial enrolled 325 patients already on a stable course...

September 29, 2020

Developments

Concert Pharmaceuticals completes alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed its open-label trial comparing once-daily versus twice-daily dosing of CTP-543 in alopecia areata patients. Alopecia areata is an autoimmune disease that causes partial or...

December 20, 2019

Developments

Concert starts Phase 2 study of adjunctive schizophrenia therapeutic candidate

Concert Pharmaceuticals (NASDAQ:CNCE) initiated a Phase 2 study to evaluate its adjunctive schizophrenia therapeutic candidate, CTP-692, in patients who are stable on an antipsychotic medication. CTP-692 is a deuterium...

December 2, 2019

Developments

Concert Pharma completes enrollment in second open label alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its second open label trial comparing once-daily versus twice-daily dosing of CTP-543, a deuterium-modified ruxolitinib, in alopecia areata patients...

September 17, 2019

Developments

Concert starts third Phase 1 study of adjunctive schizophrenia therapeutic candidate

Concert Pharmaceuticals (NASDAQ:CNCE) initiated a multiple ascending dose (MAD) study to evaluate its adjunctive schizophrenia therapeutic candidate, CTP-692, in healthy volunteers. CTP-692 is a deuterium-modified...

April 10, 2019

Feature

Concert starts multiple dose trial with CF drug

By Len Zehr Concert Pharmaceuticals (NASDAQ:CNCE), which is modifying known drugs with its deuterium technology, last week initiated a multiple ascending dose Phase 1 trial with healthy volunteers of its next generation...

November 17, 2015

Tag - CNCE

Concert Pharmaceuticals launches Phase 3 alopecia areata trial

Concert completes enrollment in Phase 2 schizophrenia trial

Concert Pharmaceuticals completes alopecia areata trial

Concert starts Phase 2 study of adjunctive schizophrenia therapeutic candidate

Concert Pharma completes enrollment in second open label alopecia areata trial

Concert starts third Phase 1 study of adjunctive schizophrenia therapeutic candidate

Concert starts multiple dose trial with CF drug

General

More